Go to Top

Recent Updates

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

We facilitate introductions to leading hedge funds who share your company's best interests and may be interested in investing in you. We also bump shoulders with some of the premier Investor Relations & PR firms in the United States. We've a track record of success which supports these relationships, and a network that feeds our success. If you have a company in need of greater visibility or capital investment, we'd like to hear from you.

Biotech News and Updates

Star Scientific (STSI): Positive Initial Results of ASAP Human Thyroid Health Study

Star Scientific, Inc. (STSI) announced the preliminary results of the Company ‘s ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyses the impact of anatabine dietary supplementation on thyroid health.

The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary supplementation in humans with autoimmune disease of the thyroid. Initial results for all study subjects suggest that dietary supplementation with anatabine ameliorates the immune system’ s targeting of the thyroid gland in autoimmune thyroiditis.

One-hundred forty-eight subjects completed the study, of which one-hundred forty six complied with

Read More

Inovio Pharmaceuticals (INO): Accelerate Development of Malaria Vaccines

Inovio Pharmaceuticals (INO) is a microcap biotech that is attempting to target the large indications of cancers and infectious diseases. The company ‘s novel pipeline is based on its SynCon® synthetic vaccine development platform. It is currently developing vaccines to address large areas of need, most notably cervical dysplasia/cancer, prostate cancer, hepatitis C virus, HIV, influenza, malaria and other tropical diseases. INO not only developed vaccines novel in nature, but also provided the administration of the therapies themselves with its unique electroporation platform.

Inovio has a phase 2 trial under-way for VGX-3100 for cervical dysplasia. Two of Inovio’ s collaborators, the University of Southampton and ChronTech Pharma AB, are

Read More

Trading Idea with Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock found a bottom after  sell-off (tax-losses) in the mid-December 2012 and now offers a solid trading opportunity.

Besides technical analysis, there are more reasons to join this trade:

CPRX announced on December 27th

Read More

 





 

 

Biotech Stocks Reviews